Blackstone and CPP Investments announced late on Friday that they're taking a majority stake in Advarra, a Columbia, Md.-based drug research services firm.
Financial terms were not disclosed but Axios confirmed that the final price was around $5 billion.
Why it matters: This is one of private equity's most anticipated and largest announced deals in North America health care so far this year.
